Pawan Dulal, Robabeh Gharaei, Adam J Berg, Adam A Walters, Nicholas Hawkins, Tim D W Claridge, Katarzyna Kowal, Steven Neill, Adam J Ritchie, Rebecca Ashfield, Adrian V S Hill, Giuseppe Tronci, Stephen J Russell, Alexander D Douglas
Adenovirus vectors offer a platform technology for vaccine development. The value of the platform has been proven during the COVID-19 pandemic. Although good stability at 2-8 °C is an advantage of the platform, non-cold-chain distribution would have substantial advantages, in particular in low-income countries. We have previously reported a novel, potentially less expensive thermostabilisation approach using a combination of simple sugars and glass micro-fibrous matrix, achieving excellent recovery of adenovirus-vectored vaccines after storage at temperatures as high as 45 °C...
October 22, 2021: Scientific Reports